Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
1.16
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-13.39 Insider Own12.15% Shs Outstand13.68M Perf Week45.18%
Market Cap15.87M Forward P/E- EPS next Y-1.31 Insider Trans10.56% Shs Float12.02M Perf Month1.75%
Income-51.09M PEG- EPS next Q-0.80 Inst Own13.05% Short Float2.58% Perf Quarter-63.62%
Sales1.55M P/S10.24 EPS this Y98.10% Inst Trans-50.99% Short Ratio0.43 Perf Half Y-96.45%
Book/sh-5.72 P/B- EPS next Y-233.75% ROA-218.66% Short Interest0.31M Perf Year-94.62%
Cash/sh0.19 P/C6.15 EPS next 5Y- ROE-584.20% 52W Range0.71 - 49.80 Perf YTD-16.55%
Dividend Est.- P/FCF- EPS past 5Y53.03% ROI- 52W High-97.67% Beta1.94
Dividend TTM- Quick Ratio0.18 Sales past 5Y-25.00% Gross Margin93.87% 52W Low64.06% ATR (14)0.13
Dividend Ex-Date- Current Ratio0.18 EPS Y/Y TTM43.32% Oper. Margin-3273.87% RSI (14)58.23 Volatility17.85% 11.37%
Employees16 Debt/Eq- Sales Y/Y TTM- Profit Margin-3295.87% Recom1.00 Target Price120.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q138.57% Payout- Rel Volume0.00 Prev Close1.16
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 11 BMO Avg Volume714.74K Price1.16
SMA2033.14% SMA50-1.87% SMA200-93.23% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Sep-27-21Upgrade ROTH Capital Neutral → Buy $2.50 → $8
Jul-01-21Initiated Guggenheim Buy $8
Jun-01-21Initiated Cantor Fitzgerald Overweight $10
May-17-21Downgrade ROTH Capital Buy → Neutral
Mar-30-21Initiated B. Riley Securities Buy $15
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
Jan-26-24 08:30AM
Jan-24-24 09:00AM
Jan-22-24 08:00AM
Jan-09-24 01:56PM
Jan-02-24 08:00AM
08:47AM Loading…
Dec-29-23 08:47AM
Dec-22-23 08:00AM
Dec-20-23 02:15PM
Dec-02-23 05:05AM
Dec-01-23 04:00PM
Nov-29-23 08:53AM
Nov-28-23 09:26PM
04:06PM
Nov-27-23 08:00AM
Nov-24-23 10:53AM
05:06AM Loading…
Nov-15-23 05:06AM
Oct-27-23 08:11AM
Oct-17-23 08:00AM
Sep-27-23 08:00AM
Sep-25-23 07:00AM
Sep-21-23 10:06AM
09:00AM
Sep-20-23 07:00AM
Sep-06-23 08:17PM
Aug-14-23 08:00AM
Aug-13-23 09:58AM
Jun-22-23 08:00AM
May-30-23 07:00AM
May-22-23 08:00AM
May-15-23 08:33AM
08:00AM Loading…
08:00AM
May-05-23 08:00AM
Apr-04-23 08:00AM
Mar-30-23 10:21AM
Mar-29-23 04:05PM
Mar-12-23 12:22PM
Mar-10-23 09:00AM
Feb-27-23 09:13AM
Feb-15-23 09:21AM
Feb-13-23 08:00AM
Feb-10-23 08:00AM
Feb-06-23 08:00AM
Dec-22-22 08:00AM
Dec-15-22 11:11AM
08:00AM
Dec-08-22 08:00AM
Nov-23-22 08:00AM
Nov-07-22 12:56PM
Nov-01-22 08:36AM
Oct-28-22 02:49PM
Oct-27-22 08:00AM
Oct-25-22 08:00AM
Sep-30-22 10:00AM
Sep-13-22 08:00AM
Sep-09-22 09:00AM
Aug-30-22 08:00AM
Aug-24-22 08:00AM
Jul-18-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 12:47PM
May-18-22 08:00AM
May-12-22 08:00AM
Apr-22-22 11:00AM
Apr-11-22 08:00AM
Mar-08-22 08:00AM
Mar-07-22 08:00AM
Feb-28-22 08:00AM
Dec-21-21 04:05PM
Dec-16-21 08:00AM
Dec-06-21 08:01AM
Nov-29-21 09:00AM
Nov-24-21 11:18AM
08:16AM
07:16AM
Nov-23-21 07:03AM
Nov-10-21 08:00AM
Nov-09-21 11:18AM
Nov-08-21 09:19AM
08:00AM
Nov-02-21 08:00AM
Oct-25-21 02:00PM
Oct-01-21 08:00AM
Sep-27-21 12:59PM
Sep-22-21 10:02AM
Sep-21-21 03:25PM
Sep-09-21 08:00AM
Sep-02-21 08:00AM
Sep-01-21 08:00AM
Aug-09-21 10:47AM
08:00AM
Jul-14-21 12:57PM
08:00AM
Jul-07-21 11:12AM
07:00AM
Jul-06-21 04:47PM
08:00AM
Jun-29-21 02:42PM
Jun-28-21 07:00AM
Jun-01-21 01:22PM
08:00AM
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra RajSee RemarksDec 01Buy1.3275,75799,999185,142Dec 01 04:16 PM
Golembiewski Michael JosephChief Financial OfficerNov 30Buy1.2183,000100,22286,450Dec 01 04:16 PM